BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Bupivacaine/Meloxicam

Risk of Serious Cardiovascular and Gastroinstestinal Events

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (5.1)  
  • ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (4, 5.1) 
  • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (5.2)

Patient Counseling Information

Package Inserts

Bupivacaine/Meloxicam

Updated November 2021